Sigyn Therapeutics (SIGY) Stock Price, News & Analysis

Company Overview

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $4.00 to $4.00
• 50-Day Range: $3.15 to $4.49
• 52-Week Range: $3.15 to $6.34
• Volume: 744 shs
• Average Volume: 483 shs
• Market Capitalization: $6.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SIGY Stock Analysis - Frequently Asked Questions

How have SIGY shares performed this year?

Sigyn Therapeutics' stock was trading at $3.15 at the start of the year. Since then, SIGY shares have increased by 27.0% and is now trading at $4.00.
View the best growth stocks for 2025 here.

How do I buy shares of Sigyn Therapeutics?

Shares of SIGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sigyn Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sigyn Therapeutics investors own include Rocket Lab USA (RKLB), Archer Aviation (ACHR), Atlas Lithium (ATLX), OriginClear (OCLN), Boxed (BOXD), bluebird bio (BLUE) and BlackSky Technology (BKSY).

Company Calendar

• Today: 3/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:SIGY
• CIK: 1642159
• Web: www.sigyntherapeutics.com
• Phone: (619) 353-0800
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,150,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,147.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.80) per share
• Price / Book: -1.43

Miscellaneous

• Outstanding Shares: 1,605,000
• Free Float: 346,000
• Market Cap: $6.42 million
• Optionable: Not Optionable
• Beta: -0.94